The mismatch repair gene MSH3 has become a major focus for therapeutic development, as unlike other mismatch repair genes, nullizygosity for MSH3 does not cause malignancies associated with mismatch repair deficiency. This evidence concerns the gene ENSG00000279284 and mismatch repair cancer syndrome 1.